



► PHARMA POOL

Jesper HØILAND

NOVO NORDISK APPOINTS NEW LEADER OF NORTH AMERICAN AFFILIATE



Jesper Høiland has been named as president of Novo Nordisk Inc., the company's North American affiliate. Mr. Høiland was previously Novo Nordisk's head of International Operations where he oversaw all of the company's operations outside of Europe, China, Japan, Korea, and North America.

Mr. Høiland joined Novo Nordisk in 1987 as assistant area manager in Denmark. He moved to marketing positions in Canada, Belgium, and France before being promoted to general manager of Novo Nordisk Australia in 1998. In 2000, he was promoted to senior VP of international marketing, and in 2004, senior VP of international operations. Under his leadership, the company's international operations region has grown its business and organization significantly, leading to the successful spinoff of China as a new, separate region in 2011, among many other achievements.

► BIOTECH POOL

Dr. Isan CHEN

MIRATI THERAPEUTICS APPOINTS CHIEF MEDICAL AND DEVELOPMENT OFFICER



Mirati Therapeutics has appointed Isan Chen, M.D., as chief medical and development officer.

Dr. Chen is a board certified hematologist and oncologist who was most recently chief medical officer of Aragon Pharmaceuticals, which was acquired by Johnson & Johnson earlier this year. At Mirati, Dr. Chen is responsible for leading the clinical development of multiple compounds in the Mirati pipeline that target some of the most promising genetic and epigenetic pathways in oncology.

Dr. Richard KENNY

IMMUNE DESIGN APPOINTS CHIEF MEDICAL OFFICER

Immune Design, a biotech company focused on the development of novel immune-based thera-



pies for cancer and other human diseases, today announced the appointment of Richard Kenney, M.D., as its chief medical officer.

A distinguished leader in vaccine development, Dr. Kenney brings extensive experience in the research, clinical, and regulatory fields from the biopharmaceutical industry, public health, and governmental environments. He has previously overseen the design, conduct, and advancement of multiple clinical programs at Crucell, Vical, and GSK Biologicals. In this new position, Dr. Kenney is leading the clinical development team at Immune Design to advance the company's novel immunotherapy product candidates.

Dr. Ferdinand MASSARI IMMUSANT NAMES CHIEF MEDICAL OFFICER



Ferdinand Massari, M.D. has joined the biopharmaceutical company ImmusanT as senior VP, development and chief medical officer. Dr. Massari is charged with overseeing the clinical development program for the therapeutic vaccine Nexvax2 for celiac disease and its companion diagnostic, as well as future development programs for other autoimmune diseases.

Dr. Massari has more than 20 years of experience in all stages of drug development and comes to ImmusanT having most recently served as a consultant providing product candidate evaluation and clinical plan development services to companies and investors.

► BIOPHARMA POOL

John BUTLER

AKEBIA THERAPEUTICS NAMES CEO



Akebia Therapeutics, a biopharmaceutical company focused on developing and commercializing small molecules to treat anemia and other diseases, has appointed John Butler as its president and CEO. Mr. Butler was most recently CEO of Inspiration Biopharmaceuticals and before that, he held several positions at Genzyme, including president of the cardiometabolic and renal division.

Dr. David ROTH INFINITY PHARMACEUTICALS ADDS TO EXECUTIVE TEAM

Infinity Pharmaceuticals has appointed David



Roth, M.D., as senior VP, clinical development and medical affairs.

In this newly created role, Dr. Roth is responsible for the clinical development organization and clinical operations. He is also charged with building and overseeing the medical affairs function. Dr. Roth serves as a member of Infinity's executive leadership team.

Dr. Roth brings to Infinity more than 20 years of experience in hematology and oncology research and development.

► EMERGING POOL

Dr. Pamela ESPOSITO

RA PHARMACEUTICALS APPOINTS CHIEF BUSINESS OFFICER



Ra Pharmaceuticals has appointed Pamela Esposito, Ph.D., as chief business officer to lead strategic and corporate development efforts for the company, which is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules.

Dr. Esposito was most recently senior VP, strategic planning and business development at Angiochem Inc., where she was instrumental in executing several important collaborations for the company.

► CRO POOL

Dr. Gregory DENNIS

PPD NAMES VP OF GLOBAL PRODUCT DEVELOPMENT



Pharmaceutical Product Development (PPD) has appointed Gregory Dennis, M.D., as VP of global product development. In this role, Dr. Dennis serves as therapeutic area head, providing medical and scientific expertise for rheumatology, immunology, and inflammatory diseases.

Dr. Dennis comes to PPD from UCB, where he served as head of immunology for U.S. medical affairs and participated extensively in guiding compounds through the regulatory approval process.

MORE People are Talking **MORE** Often on **MORE** Diverse and Intriguing Topics.

A Portfolio of Integrated Media Solutions brought to you by PharmaVOICE

PharmaVOICE Magazine

The premier executive forum publication that allows business leaders to engage in candid dialogues on the myriad challenges and trends impacting the life-sciences industry.

PharmaVOICE — Showcase Features

Content-specific articles that are designed to feature contributed thought-leader essays from service providers. The topics addressed are supported by insights from industry leaders in PharmaVOICE's unique feature article format.

PharmaVOICE.com

An online community-portal with searchable content, access to current and archived issues, and interactive polling and discussion boards.



WebLinx Interactive WebSeminars

Sophisticated online media-facilitated discussions that unite buyers and sellers via a permission-based marketing medium for maximum quality lead generation.

Sponsored E-Surveys

Electronic-based questionnaires designed to identify customer behavior, needs, and preferences complete with back-end analysis.

PharmaVOICE MarketPlace

A comprehensive in-print and online directory of companies, products, and services for the life-sciences market.

E-Alerts

Updates on the latest print and online offerings from PharmaVOICE delivered to our print and online community via e-mail.

Sponsored Podcasts

Rapidly growing audio syndication medium that connects thought leaders with a motivated audience.

For more information about these exciting opportunities call (609)730-0196 to speak with Lisa Banket, Publisher (lbanket@pharmavoice.com), or contact Cathy Tracy (203)778-1463, (ctracy@pharmavoice.com), or Trish Kane (484)412-8596 (tkane@pharmavoice.com),

Read. Think. Participate.

www.pharmavoice.com

Joseph SGHERZA**THEOREM CLINICAL RESEARCH
NAMES HEAD OF INFECTIOUS
DISEASE FRANCHISE**

A veteran of 24 years in the pharmaceutical, biotechnology, and CRO industries, Joseph Sgherza has been named VP of biopharmaceutical development for the infectious disease franchise of Theorem Clinical Research.

Before joining Theorem, Mr. Sgherza was portfolio director for Parexel International, where he was responsible for the operational execution of pharmaceutical trials in infectious disease, biologics, and oncology.

► AGENCY POOL**Peter MOLLEGARD****MEDEVOKE HIRES NEW SENIOR DIRECTOR
OF CLIENT SERVICE**

MedEvolve, a division of Medisys Health Communications, has added Peter Mollegard as its new senior director of client service.

Mr. Mollegard has worked in client services in the healthcare communications field for more than 10 years, and is known for his innovative and strategic thinking while leading internal teams in executing million-dollar initiatives for healthcare audiences across various categories.

Miriam SWAIN**Tiberiu VASTAG****TOPIN ADDS USER EXPERIENCE DESIGNER
AND SENIOR DIGITAL PROJECT MANAGER**

Topin & Associates, a full-service medical marketing communications agency in Chicago, has expanded its staff by adding Miriam Swain as a senior digital project manager and Tiberiu Vastag as a user experience (UX) designer. Both help Topin keep in sync with the growing demand for digital work.



Ms. Swain joins Topin from the consumer ad agency shop Meyers & Partners, where she lead its online brand planning, positioning, and launch initiatives.

Mr. Vastag has more than 15 years of experience in interactive design and front-end development.

► ASSOCIATION POOL**Dr. Reid BLACKWELDER****AMERICAN ACADEMY OF FAMILY
PHYSICIANS NAMES PRESIDENT**

Reid Blackwelder, M.D., a family physician in Kingsport, Tenn., has assumed the role of president of the American Academy of Family Physicians. Previously, he served three years as a director on the AAFP board and a year as president-elect.

As president of the AAFP, Dr. Blackwelder will advocate on behalf of family physicians and patients nationwide to inspire positive change in the U.S. healthcare system. Outside the AAFP, he serves as director of the medical student education division for the department of family medicine at East Tennessee State University's James H. Quillen College of Medicine in Johnson City, Tenn., where he is also a professor of family medicine.

He previously served as program director of the Kingsport Family Medicine residency program of ETSU for more than 13 years and remains on faculty at the residency.

The AAFP represents 110,600 physicians and medical students nationwide.

► TECHNOLOGY POOL**Denis CONNAGHAN****Tim IMMEL****CLINVERSE NAMES CEO**

Clinverse, a global technology and eclinical commerce network for clinical trials, has added Denis Connaghan as CEO. Mr. Connaghan brings more than 25 years of substantial commercialization experience across industry sectors including technology, healthcare, insurance, life sciences, and IT.

Before joining Clinverse, he served as a management consultant and in interim executive roles at GMA Healthcare, Infina Connect, and several other life science IT and services companies.

With the announcement of Mr. Connaghan as CEO, Tim Immel, founder and former CEO of Clinverse, takes on the role of chief product officer. **PV**



USE YOUR QR CODE READER
OR GO TO
bit.ly/PV1113-TalentPool

**STATEMENT OF OWNERSHIP,
MANAGEMENT,
AND CIRCULATION**

1. Publication title: PharmaVOICE
2. Publication no.: #23626
3. Filing date: September 26, 2013
4. Issue frequency: published monthly except combined issues in July/August and Nov./Dec.
5. No. of issues published annually: 10
6. Annual subscription price: US: \$190. Non-US: \$360.
7. Complete mailing address of known office of publication: PharmaLinx LLC, 244 Jacobs Creek Road, Titusville, NJ 08560, Titusville, NJ 08560
8. Complete mailing address of headquarters or general business office of publisher: PharmaLinx LLC, 244 Jacobs Creek Road, Titusville, NJ 08560, Titusville, NJ 08560
9. Full names and complete mailing addresses of publisher, editor, and managing editor: Lisa Banket, P.O. Box 327, Titusville, NJ 08560, Taren Grom, P.O. Box 327, Titusville, NJ 08560, and Denise Myshko, P.O. Box 327, Titusville, NJ 08560
10. Owner: Lisa Banket, Taren Grom, and Marah Walsh
11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: (none)
13. Publication title: PharmaVOICE
14. Issue date for circulation data below: September 2013
15. Extent and nature of circulation (avg. no. copies each issue during preceeding 12 months and actual no. copies of single issue published nearest to filing date, respectively). Total no. copies - 18,055 and 18,000. Individual paid/requested mail subscriptions stated on Form 3541: 17,553 and 17,565. Sales through dealers and carriers, street vendors, counter sales, and other paid or requested distribution outside USPS: 19 and 5. Total paid and/or requested circulation: 17,572 and 17,570. Nonrequested copies stated on Form 3541: 0 and 0.
- Free or nominal rate distributed outside the mail: 186 and 170. Total free or nominal rate distributed: 261 and 242. Total distribution: 17,833 and 17,812. Copies not distributed: 222 and 188. Total: 18,055 and 18,000. Percent paid and/or requested circulation: 98.5 and 98.6.
16. This statement of ownership will be printed in the November/December 2013 issue of this publication.
17. I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties). (Signed) Marah Walsh, Founding Partner



18th Annual

DRUG DELIVERY PARTNERSHIPS™

The Only Event that Connects Senior Executives Through
Best-In-Class Education and Innovative Technology

January 27-29, 2014
Boca Raton Resort & Club
Boca Raton, FL

Moving Innovation from Concept to Marketable Success

DDP14 is the roadmap to your share of the
\$224 billion drug delivery market. **Start here.**



Driving True Innovation in Life Sciences by
Defining and Meeting the Unmet Need

Alfred Mann

Chief Executive Officer and Chairman of the Board
MANNKIND CORPORATION

2014 KEYNOTE



The Future of Drug Delivery Technologies

Fernando Sallés, PhD, CLP

Executive Director, Strategic Licensing & Acquisitions Lead,
Ophthalmics and Drug Delivery Technologies
MERCK RESEARCH LABORATORIES

2014 KEYNOTE



Jumpstart your next multi-million dollar deal
with state-of-the-art one-to-one partnering

powered by

partneringONE®



Plus! Human Factors • Connected Health • Informatics • and more!

Register at **www.DDPEvent.com** or call **(888) 670-8200**

*valid after November 15, 2013
and only applicable to the standard registration rate

Talent Pool

► **BIOPHARMA POOL**

J. Kevin BUCHI
Lesley RUSSELL

**TETRALOGIC PHARMACEUTICALS
ANNOUNCES NEW EXECUTIVES**

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule SMAC mimetic drugs to treat cancer, has appointed J. Kevin Buchi as president and CEO, and Lesley Russell as chief operating officer.

Mr. Buchi was most recently corporate VP, global branded products, at Teva Pharmaceutical Industries.

Dr. Russell is a hematologist/oncologist with more than 20 years of international pharmaceutical industry experience and leadership in the therapeutic areas of hematology/oncology, neurology, psychiatry, pain and inflammation, respiratory medicine, cardiovascular medicine, and stem cell therapy. Dr. Russell was most recently senior VP and global head, research and development, global branded products, for Teva Pharmaceuticals.

Dr. Peter KIENER

**AMBRX APPOINTS CHIEF SCIENTIFIC
OFFICER**

Ambrx, a clinical stage biopharmaceutical company, has named Peter Kiener, Ph.D., as chief scientific officer. Dr. Kiener brings decades of expertise in the development of next-generation biologic therapeutics, including multi-specific, antibody based biologics while president, CEO, and co-founder of Zynigena.

► **SPECIALTY POOL**

Jeffrey DUCHEMIN

HARVARD BIOSCIENCE NAMES NEW CEO

Harvard Bioscience, a global developer, manufacturer, and marketer of a broad range of tools to advance life-science research and regenerative medicine, has hired Jeffrey Duchemin, a veteran life science executive, as its CEO.

► **CRO POOL**

Jamie GAULT
Deborah TURUNJIAN
Kathleen ZAJD

**NOVELLA CLINICAL ANNOUNCES
NEW LEADERSHIP ROLES**

Novella Clinical, a full-service clinical research organization, has moved three senior executives into new leadership roles within the organization.

Jamie Gault has been promoted to global head of regulatory affairs to oversee preparation of regulatory packages for agencies globally. Having joined Novella in 2012 in a senior quality assurance role, Ms. Gault has 25 years experience in regulatory roles both at sponsor and CRO organizations. Her regulatory authority interactions span drugs, biologics, cell and tissue-based products, combination products and medical devices.

Deborah Turunjian has been named VP, oncology clinical development, to further expand Novella's dedicated oncology division. Previously, Ms. Turunjian served as executive leadership for Novella's business optimization and vendor management departments in addition to her oversight of western U.S. business operations.

Kathleen Zajd has been named VP, global quality and compliance. She became an integral part of the Novella senior management team as a result of Novella's acquisition of Prologue Research International in 2010. Before co-founding Prologue, Ms. Zajd held leadership roles in clinical operations, regulatory and quality with experience spanning more than 25 years across both service organizations and pharmaceutical and medical device companies.

Patricia MONTEFORTE

**APTIV SOLUTIONS APPOINTS PRESIDENT OF
TRIO CLINICAL RESOURCING**

Aptiv Solutions, a global biopharmaceutical and medical device development services company, has appointed Patricia Monteforte to the role of president of Trio Clinical Resourcing, an Aptiv Solutions subsidiary devoted to clinical and regulatory staffing. Ms. Monteforte will leverage more than 25 years in the pharmaceutical industry and success leading clinical research organizations to assemble teams of qualified clinical and regulatory professionals to deliver flexible resourcing solutions to meet the current and future challenges in the pharmaceutical and medical device industry.

► **AGENCY POOL**

Sara CRAWFORD
Kimberly ROMAGNOLA

CENTRON ADDS NEW STAFF MEMBERS

Centron, a full-service medical communications agency, has added several new staff members.

Mary Anne Carter joins Centron as an account group supervisor, bringing with her eight years of experience in the medical communications industry.

Sara Crawford has been named VP account group supervisor of Centron. She brings 15 years of healthcare communications experience with a

focus in oncology. She was previously with Brand Pharm and Saatchi & Saatchi Health.

Jenny Krieger has been named as a senior account executive. She joins the agency from Grey Healthcare Group.

Doug Levy brings to Centron more than 20 years of experience in medical advertising, education, and promotion. As senior VP, management supervisor, he provides expertise in marketing and creative strategy.

Kaitlyn McNamara joins the Centron team as a senior art director. She was formerly an art director with Harrison and Star.

Jackie Ngai, account group supervisor, joins Centron from DraftFCB.

Shilpa Patel, account supervisor, joins Centron from Saatchi & Saatchi Health.

Kimberly Romagnola brings more than 20 years of experience to Centron as senior VP, managing director. She previously held senior VP positions at DraftFCB and Cline Davis & Mann.

Eva Schicker joins the team as a senior art director with more than 17 years of pharmaceutical advertising experience. She was VP, associate creative director of art, at Euro RSCG Life.

Warren Van Name brings more than 20 years of experience to Centron as a senior project Manager. He has held similar positions at agencies such as Cline Davis & Mann and GlobalHue.

► **CONSULTING POOL**

Dr. Stephen SUN

**PARAGONRX NAMES FORMER FDA
OFFICIAL AS CHIEF MEDICAL OFFICER**

ParagonRx, an inVentiv Health company offering product safety risk management and healthcare systems consulting to pharmaceutical and medical device companies, has appointed Stephen Sun, M.D., as chief medical officer, advising clients on regulatory and safety issues.

Dr. Sun, formerly with the FDA, reports directly to ParagonRx President Jeffrey Fetterman


► **TECHNOLOGY POOL**

Steven HERNE

ERT NAMES CHIEF COMMERCIAL OFFICER

ERT, a global solution provider for patient safety and efficacy endpoint data collection, has appointing Steven Herne as executive VP and chief commercial officer.

Mr. Herne has more than 19 years of experience in the pharmaceutical industry, of which he spent the last 14 years focused on business development, strategic development, product management, and marketing. **PV**



The TrialCard Difference

Orchestrating Solutions for the Life Cycle of Your Brand.

Analytics • Patient Access • Point - of - Sale • Point - of - Care • Adherence

Contact us today and let us show you how our proven notes can help your brand.

p 1.877.343.1238
e info@trialcard.com

www.trialcard.com



trialcard[®]
Access. Acquisition. Adherence.



Transforming Promising Ideas into Commercial Reality

At inVentiv Health there are no silos—only the seamless convergence of Clinical, Commercial, and Consulting services delivered by 12,000 people working together around the globe.

Our clients say we solve problems no one else can, and turn to us for outcomes that are strategic, cost-effective and fast.

How can we help you?

>> CONVERGENCE IN ACTION:

The world is awash in apps and mobile devices that track users' vital signs, calorie intake, exercise, sleep, mood, medications, and more. At Palio+Ignite, our researchers analyze data and the impact of these tools that are the foundation of the Quantified Self movement, today increasingly more mainstream. We do this to give physicians a sharper picture of their patients and to help pharma companies see how products perform in the real world. Palio+Ignite understands where the industry is going, and we're invested in providing analytics and insights never seen before. This is what we offer clients—communications expertise and the vast resources of inVentiv Health.